Perioperative ketorolac in high risk breast cancer patients. Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial.
Ketorolac, a NSAID routinely used during surgery proposed to have anticancer effects, is a promising way to improve postoperative oncological outcome. This effect may be particularly prominent in patients with elevated preoperative inflammatory scores, like the neutrophil:lymphocyte ratio. In this paper, we describe the rationale, the preliminary analyses in our patients, the feasibility and the methodology of a prospective randomized trial called "Ketorolac in Breast Cancer trial" (KBCt) (NCT01806259).
Department of Anesthesiology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium. Electronic address: forgetpatrice@yahoo.fr.
Patrice
P
Forget
Martine
M
Berlière
Aline
A
van Maanen
Francois P
FP
Duhoux
Jean-Pascal
JP
Machiels
Pierre G
PG
Coulie
Gauthier
G
Bouche
Marc
M
De Kock
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000188:drug therapy*; D020910:Ketorolac / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D018579:Patient Selection; D059035:Perioperative Period; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D018401:Sample Size
D000894:Anti-Inflammatory Agents, Non-Steroidal; D020910:Ketorolac